PMID- 27713640
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220309
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 9
DP  - 2016
TI  - The efficacy and safety of nivolumab in previously treated advanced 
      non-small-cell lung cancer: a meta-analysis of prospective clinical trials.
PG  - 5867-5874
AB  - BACKGROUND: Nivolumab (BMS-936558/ONO-4538) was the first monoclonal antibody 
      targeting programmed death (PD)-1. So far, a number of clinical trials on 
      nivolumab have showed satisfactory efficacy in treating non-small-cell lung 
      cancer (NSCLC). Herein, we present a meta-analysis evaluating the efficacy and 
      safety of nivolumab for previously treated advanced NSCLC patients. METHODS: 
      Electronic databases were searched for eligible literature. Data of objective 
      response rate (ORR), disease control rate, overall survival, progression-free 
      survival, and adverse effects (AEs) were extracted and pooled. Outcomes analyzed 
      and presented in this study were according to the original data from nivolumab 3 
      mg/kg. RESULTS: In general, nine trials with 817 patients were included in this 
      meta-analysis. The pooled ORR, disease control rate, 1-year overall survival 
      rate, and 1-year progression-free survival rate were 20% (95% confidence interval 
      [CI]: 17%-23%), 36% (95% CI: 22%-51%), 47% (95% CI: 40%-53%), 21% (95% CI: 
      18%-24%), respectively. In addition, the rate of grade 3-4 AEs was only 8% (95% 
      CI: 6%-12%). Subgroup analysis showed no significant difference in terms of ORR 
      between squamous and non-squamous NSCLC (odds ratio 1.23, 95% CI: 0.63-2.39, 
      P=0.51). However, significantly greater ORR was presented in programmed cell 
      death ligand 1 (PD-L1) positive cohort (ORR 31%, 95% CI: 24%-38%), compared to 
      PD-L1 negative cohort (ORR 12%, 95% CI: 9%-17%). The odds ratio for objective 
      response to nivolumab in PD-L1 positive cases relative to negative cases was 3.08 
      (95% CI: 1.87-5.08, P<0.0001). CONCLUSION: In conclusion, nivolumab is a 
      promising second-line agent for previously treated advanced NSCLC with manageable 
      AEs. Both squamous and non-squamous NSCLC patients showed similar efficacy. In 
      addition, patients with positive PD-L1 expression had better response from 
      nivolumab. MICROABSTRACT: We present a meta-analysis evaluating the efficacy and 
      safety of nivolumab for previously treated advanced NSCLC patients. In our study, 
      nivolumab is a promising second-line agent for previously treated advanced NSCLC 
      with manageable AEs. Both squamous and non-squamous NSCLC patients showed similar 
      efficacy. In addition, patients with positive PD-L1 expression had better 
      response from nivolumab.
FAU - Huang, Jiaxing
AU  - Huang J
AD  - Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key 
      Laboratory of Oncology in South China.
FAU - Zhang, Yaxiong
AU  - Zhang Y
AD  - Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key 
      Laboratory of Oncology in South China.
FAU - Sheng, Jin
AU  - Sheng J
AD  - Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key 
      Laboratory of Oncology in South China.
FAU - Zhang, Hongyu
AU  - Zhang H
AD  - Department of Medical Oncology, the Fifth Affiliated Hospital of Sun Yat-Sen 
      University, Zhuhai, Guangdong, People's Republic of China.
FAU - Fang, Wenfeng
AU  - Fang W
AD  - Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key 
      Laboratory of Oncology in South China.
FAU - Zhan, Jianhua
AU  - Zhan J
AD  - Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key 
      Laboratory of Oncology in South China.
FAU - Zhou, Ting
AU  - Zhou T
AD  - Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key 
      Laboratory of Oncology in South China.
FAU - Chen, Ying
AU  - Chen Y
AD  - Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key 
      Laboratory of Oncology in South China.
FAU - Liu, Lin
AU  - Liu L
AD  - Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key 
      Laboratory of Oncology in South China.
FAU - Zhang, Li
AU  - Zhang L
AD  - Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key 
      Laboratory of Oncology in South China.
LA  - eng
PT  - Journal Article
DEP - 20160923
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC5045236
OTO - NOTNLM
OT  - PD-1
OT  - meta-analysis
OT  - nivolumab
OT  - non-small-cell lung cancer (NSCLC)
EDAT- 2016/10/08 06:00
MHDA- 2016/10/08 06:01
PMCR- 2016/09/23
CRDT- 2016/10/08 06:00
PHST- 2016/10/08 06:00 [entrez]
PHST- 2016/10/08 06:00 [pubmed]
PHST- 2016/10/08 06:01 [medline]
PHST- 2016/09/23 00:00 [pmc-release]
AID - ott-9-5867 [pii]
AID - 10.2147/OTT.S115262 [doi]
PST - epublish
SO  - Onco Targets Ther. 2016 Sep 23;9:5867-5874. doi: 10.2147/OTT.S115262. eCollection 
      2016.